BLAINJECTIONINJECTABLE
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
IRA Negotiated
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETICOVO (etanercept-ykro) is a biosimilar fusion protein that mimics the mechanism of the reference etanercept by binding TNF-alpha and blocking its inflammatory signaling. It is administered via injection for autoimmune and inflammatory conditions. This product represents Samsung Bioepis's entry into the established TNF inhibitor market as a follow-on biologic.
Peak
Peak lifecycle with significant IRA price negotiation pressure signals mature market consolidation; expect stable but increasingly price-competitive team structures.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Samsung Bioepis is hiring 4 roles related to this product
Worked on ETICOVO at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.